Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PHPhio Pharmaceuticals Corp. logo

Phio Pharmaceuticals Corp. (PHIO)

NASDAQ · Currency in USD
$0.85 ▼ -0.02 (-2.30%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.92 ▲ +0.07 (+7.65%)
After hours: Oct 23, 4:35 PM ET

Summary

Previous Close
$0.87
Open
$0.88
Day's Range
$0.85 – $0.89
52 Week Range
$0.81 – $4.19
Volume
28,713
Avg. Volume
468,938
Market Cap
$9.90M
Beta (5Y Monthly)
0.84
PE Ratio (TTM)
--
EPS (TTM)
-$1.11
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Phio Pharmaceuticals Corp.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
6
CEO
Robert L. Bitterman

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.36
DateEst.Actual
Aug 6, 2026-$0.36-$0.36Beat
May 7, 2026-$0.24-$0.34Miss
Mar 5, 2026-$0.34-$0.15Beat
Nov 13, 2025-$0.45-$0.44Beat
Aug 14, 2025-$0.36-$0.45Miss
May 15, 2025–-$0.41

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PHIO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.